Biomea Fusion, INC 10-K annual reports
Annual reports — audited financials, the full risk-factor list, and management’s account of the year.
NASDAQ
Biomea Fusion, a clinical-stage biopharmaceutical company, reported a reduced net loss in 2025 but faces substantial doubt about its ability to continue as a going concern, while strategically focusing on diabetes and obesity treatments.
NASDAQ
10-K: Biomea Fusion Shifts Focus to Diabetes and Obesity, Announces Leadership Change in 10-K Filing
Biomea Fusion's 10-K filing reveals a strategic shift towards diabetes and obesity treatments, alongside a leadership transition and updates on clinical programs.
NASDAQ
Biomea Fusion's 10-K filing highlights its clinical-stage progress in developing covalent small molecule drugs for genetically defined cancers and metabolic diseases, particularly diabetes.